PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
May 30, 2026Journal of Clinical Oncology

Integrated NAL-IRI/5-FU/LV, benmelstobart, anlotinib with or without immunoradiotherapy for second-line metastatic pancreatic cancer: A phase II dual-cohort study.

View Full Paper
Ask AI
Bookmark
Share

Authors

JDJuan DuXKXiang KongHSHui-zi Sha

Discussion

Loading...

Member takes

Overview

Phase II study evaluates an integrated therapy for second-line metastatic pancreatic cancer, suggesting enhanced outcomes with added immunoradiotherapy.

Key Points

  • This study aims to evaluate the efficacy and safety of an integrated regimen for patients with second-line metastatic pancreatic cancer.
  • Enrollment of 46 patients aged 18–75 with confirmed metastatic pancreatic cancer who progressed after first-line therapy.
  • Patients received NAL-IRI/5-FU/LV, benmelstobart, and anlotinib, with Cohort A receiving systemic therapy and Cohort B receiving additional SBRT.
  • Primary endpoint was objective response rate (ORR), with secondary endpoints including disease control rate (DCR) and progression-free survival (PFS).
  • Overall ORR was 25.0%, with Cohort A at 17.4% and Cohort B at 38.5%.
  • DCR was 69.4%, significantly higher in Cohort B (92.3%) compared to Cohort A (56.5%) with P=0.031.
  • Median PFS was 4.7 months overall, with 4.3 months for Cohort A and 7.1 months for Cohort B.

Cite This Study

Du et al. (2026) studied this question.

synapsesocial.com/papers/6a1a7fce0307b78509431ef3https://doi.org/10.1200/jco.2026.44.16_suppl.e16374
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line treatment for metastatic pancreatic adenocarcinoma: a multicentre, single-arm, phase II trial2025
  2. 2Irinotecan plus anlotinib or further in combination with penpulimab as second-line treatment of metastatic colorectal cancer (ZL-IRIAN).2024 · 1 citations
  3. 3PD-1 blockade plus chemotherapy followed by concurrent SBRT with SIB as preoperative therapy for patients with potentially resectable pancreatic cancer: A single-arm phase 2 study.2024 · 1 citations
  4. 4Integrated penpulimab (a PD-1 inhibitor), anlotinib (an antiangiogenic targeted drug), nab-paclitaxel and gemcitabine as first-line regimen for metastatic pancreatic cancer: A multi-centered, randomized controlled trial (RCT-PAAG).2026
  5. 5First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial2024 · 38 citations